Claude Preudhomme

Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes.

M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).

Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.

Linezolid induces ring sideroblasts.

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists.

High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.

Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.

SNP-array lesions in core binding factor acute myeloid leukemia.